Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Neurology

Understanding the Biology and Antibody Types

At a Glance

Autoimmune limbic encephalitis (ALE) occurs when the immune system mistakenly attacks the brain's memory and emotion center. The specific antibody involved—either on the cell surface or inside the cell—determines your cancer risk, symptom severity, and response to immunotherapy.

Autoimmune limbic encephalitis (ALE) occurs when the immune system—which normally protects the body from germs—mistakenly attacks the brain [1]. Specifically, it targets the limbic system (the brain’s emotional and memory center), causing inflammation and disruption of normal brain signals [2].

The “biology” of your condition depends almost entirely on where the immune system is attacking. Doctors categorize these attacks based on whether the target is on the outside (surface) of a brain cell or tucked away on the inside (intracellular) [3][4].

The Two Main Types of Attacks

1. Surface Antibodies (The “Removable” Attack)

Some antibodies target proteins located on the cell surface—the “skin” of the brain cell. Because these targets are accessible, the antibodies themselves can directly cause the symptoms [3].

  • Response to Treatment: These typically respond very well to immunotherapy (treatments like steroids or IVIG that remove or calm antibodies) because the medicine can easily reach the area being attacked [3][4].
  • Common Markers:
    • LGI1: Usually not linked to cancer. It often causes very brief facial or arm jerks [5][6].
    • CASPR2: May be associated with a thymoma (a tumor of the thymus gland) and can cause muscle stiffness or nerve pain [7][8].

2. Intracellular Antibodies (The “Signal” Attack)

Other antibodies target proteins located inside the brain cell. These antibodies are often just “smoke” signaling a deeper “fire”: a hidden cancer elsewhere in the body [3][9]. These are often called paraneoplastic markers.

  • Response to Treatment: These often respond poorly to immunotherapy alone. This is because the actual damage is frequently caused by T-cells (killer cells) that have entered the brain to attack what they think are infected cells [10][11]. While this sounds frightening, immunotherapy is specifically designed to stop these T-cells in their tracks. However, the most effective long-term treatment for paraneoplastic cases is finding and removing the underlying tumor [3].
  • Common Markers:
    • Hu: Strongly linked to small-cell lung cancer [9].
    • Ma2: Often linked to testicular tumors [3].
    • GAD65: A unique case where the target is inside the cell, but it may not always be linked to cancer. It is highly associated with long-term epilepsy [12][11].

Why the Distinction Matters

Understanding your specific antibody subtype helps your medical team predict two critical things: your recovery and your cancer risk.

Feature LGI1, CASPR2 Anti-NMDAR Intracellular Antibodies (e.g., Hu, Ma2)
Main “Weapon” Surface Antibodies [3] Surface Antibodies [3] T-Cells (Killer cells) [10]
Cancer Link Lower (Non-paraneoplastic) [3] Moderate-High (Ovarian Teratoma) [3] Very High (Paraneoplastic) [9]
Treatment Success Often high with immunotherapy [4] High, especially if tumor is removed [3] Lower without tumor removal [3]

Note: Anti-NMDAR acts on the surface like LGI1, but carries a much higher paraneoplastic risk for young women, necessitating distinct screening [3].

The Role of the Limibic System

Regardless of the antibody type, the attack focuses on the medial temporal lobe, where the hippocampus resides [1]. Because this area is the “hard drive” for your memory and the “thermostat” for your emotions, an attack here leads to the rapid memory loss and personality changes characteristic of ALE [2]. Screening for these markers through blood or spinal fluid tests is the only way to know exactly which biological battle is taking place [13][14].

Common questions in this guide

What is the difference between surface and intracellular antibodies in ALE?
Surface antibodies attack the outside of brain cells and typically respond very well to immunotherapy. Intracellular antibodies target the inside of cells, are often linked to a hidden cancer in the body, and usually require treating the underlying tumor for the best recovery.
Does having autoimmune limbic encephalitis mean I have cancer?
Not always. While some intracellular antibodies (like Hu or Ma2) are highly linked to hidden cancers, many surface antibodies (like LGI1) are usually not associated with cancer. Your doctor will use your specific antibody test results to determine if cancer screening is necessary.
Why does ALE cause memory loss and personality changes?
Autoimmune limbic encephalitis targets the limbic system, specifically an area called the hippocampus. Because the hippocampus acts as the brain's control center for memories and emotions, inflammation in this area leads to rapid memory issues and mood or personality changes.
Will immunotherapy cure my autoimmune limbic encephalitis?
Your response to immunotherapy depends heavily on your antibody type. Patients with surface antibodies often respond very well to treatments like steroids or IVIG. If you have intracellular antibodies, immunotherapy is less effective on its own, and finding and treating any underlying tumor is critical.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific antibody was found in my test results, and is it a surface or an intracellular type?
  2. 2.Does the presence of this antibody mean we should be looking for a hidden tumor (paraneoplastic)?
  3. 3.How does the location of this antibody (surface vs. inside the cell) affect my chances of responding to immunotherapy?
  4. 4.If my antibody is intracellular, like GAD65 or Hu, are there different treatment approaches we should consider since standard immunotherapy might be less effective?
  5. 5.Is there a high risk of this developing into chronic epilepsy based on the specific antibody identified?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Autoimmune encephalitis: what the radiologist needs to know.

    Sanvito F, Pichiecchio A, Paoletti M, et al.

    Neuroradiology 2024; (66(5)):653-675 doi:10.1007/s00234-024-03318-x.

    PMID: 38507081
  2. 2

    Neuropsychological Performance in Autoimmune Limbic Encephalitis: Evidence from an Immunotherapy-Naïve Cohort.

    Mueller C, Langenbruch L, Rau JMH, et al.

    Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists 2022; (37(4)):738-752 doi:10.1093/arclin/acac001.

    PMID: 35136904
  3. 3

    Diagnosis and Clinical Features in Autoimmune-Mediated Movement Disorders.

    Hsieh PC, Wu YR

    Journal of movement disorders 2022; (15(2)):95-105 doi:10.14802/jmd.21077.

    PMID: 35670020
  4. 4

    LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes.

    Binks SNM, Klein CJ, Waters P, et al.

    Journal of neurology, neurosurgery, and psychiatry 2018; (89(5)):526-534 doi:10.1136/jnnp-2017-315720.

    PMID: 29055902
  5. 5

    Anti-LGI1-antibody autoimmune encephalitis as a neurological paraneoplastic syndrome associated with gastrointestinal stromal tumour: a case report.

    Kwaszewska AD, Betka M, Jastrzębski K

    Postepy psychiatrii neurologii 2025; (34(2)):108-115 doi:10.5114/ppn.2025.150016.

    PMID: 40666614
  6. 6

    Clinical Characteristics and Short-Term Prognosis of Autoimmune Encephalitis: A Single-Center Cohort Study in Changsha, China.

    Deng S, Qiu K, Liu H, et al.

    Frontiers in neurology 2019; (10()):539 doi:10.3389/fneur.2019.00539.

    PMID: 31178819
  7. 7

    Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features.

    Muñiz-Castrillo S, Joubert B, Elsensohn MH, et al.

    Journal of neurology, neurosurgery, and psychiatry 2020; (91(10)):1076-1084 doi:10.1136/jnnp-2020-323226.

    PMID: 32651251
  8. 8

    Thymoma and Autoimmune Encephalitis: Clinical Manifestations and Antibodies.

    Guasp M, Landa J, Martinez-Hernandez E, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2021; (8(5)) doi:10.1212/NXI.0000000000001053.

    PMID: 34301822
  9. 9

    Autoimmune Encephalitis and Paraneoplastic Neurologic Syndromes: A Nationwide Study on Epidemiology and Antibody Testing Performance.

    Kerstens J, Schreurs MWJ, de Vries JM, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2024; (11(6)):e200318 doi:10.1212/NXI.0000000000200318.

    PMID: 39467237
  10. 10

    Impact of T cells on neurodegeneration in anti-GAD65 limbic encephalitis.

    Dik A, Widman G, Schulte-Mecklenbeck A, et al.

    Annals of clinical and translational neurology 2021; (8(12)):2289-2301 doi:10.1002/acn3.51486.

    PMID: 34841709
  11. 11

    Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis.

    Spatola M, Dalmau J

    Current opinion in neurology 2017; (30(3)):345-353 doi:10.1097/WCO.0000000000000449.

    PMID: 28234800
  12. 12

    The limbic and extra-limbic encephalitis associated with glutamic acid decarboxylase (GAD)-65 antibodies: an observational study.

    Kuang Z, Baizabal-Carvallo JF, Alonso-Juarez M, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2025; (46(6)):2765-2777 doi:10.1007/s10072-024-07933-7.

    PMID: 39704979
  13. 13

    Differences and diversity of autoimmune encephalitis in 77 cases from a single tertiary care center.

    Saraya AW, Worachotsueptrakun K, Vutipongsatorn K, et al.

    BMC neurology 2019; (19(1)):273 doi:10.1186/s12883-019-1501-5.

    PMID: 31694559
  14. 14

    Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes.

    Déchelotte B, Muñiz-Castrillo S, Joubert B, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2020; (7(3)) doi:10.1212/NXI.0000000000000701.

    PMID: 32170044

This page explains the biology and antibody types of autoimmune limbic encephalitis for educational purposes. Always consult your neurologist or healthcare provider to interpret your specific antibody test results and determine your treatment plan.

Get notified when new evidence is published on Autoimmune limbic encephalitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.